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Flow cytometryThemost prominent factor that delays the translation of cell-free DNA (cfDNA) analyses to clinical practice is the
lack of knowledge regarding its origin and composition. The elucidation of the former is complicated by the
seemingly random ﬂuctuation of quantitative and qualitative characteristics of cfDNA in the blood of healthy
and diseased individuals. Besides methodological discrepancies, this could be ascribed to a web of cellular
responses to various environmental cues and stressors. Since all cells release cfDNA, it follows that the cfDNA
in the blood of cancer patients is not only representative of tumor derived DNA, but also of DNA released by
healthy cells under different conditions. Additionally, cfDNA released by malignant cells is not necessarily just
aberrant, but likely includes non-mutated chromosomal DNA fragments. This may cause false positive/negative
results. Althoughmany have acknowledged that this is a major problem, few have addressed it. We propose that
many of the current stumbling blocks encountered in in vivo cfDNA studies can be partially circumvented by
in vitromodels. Accordingly, the purpose of this work was to evaluate the release of cfDNA from cultured cells
and to gauge its potential use for elucidating the nature of cfDNA. Results suggest that the occurrence of cfDNA
is not a consequence of apoptosis or necrosis, but primarily a result of actively secreted DNA, perhaps in associ-
ationwith a protein complex. This study demonstrates the potential of in vitro cell culturemodels to obtain useful
information about the phenomenon of cfDNA.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Understanding the processes involved in the generation of cell-free
DNA (cfDNA) is critical for inferring its role in biology and pathology,
and expediting the translation of analyses to clinical practice. However,
despite the apparent ubiquity of cfDNA in bioﬂuids, the elucidation of its
origin has only been a partial victory. Excluding exogenous DNA
(bacterial, viral and parasitic, for instance), several possible sources
and cognatemechanisms have been advocated. Firstly, it was presumed
that cfDNA enters the blood following the lysis of cells on the interface
between a tumor and circulation. Since it was shown that the concen-
tration of cfDNA in the blood of cancer patients is greater than could
be accounted for by the mass of cells present [1], this notion has been
abandoned. Secondly, it was proposed that cfDNA may originate from
the destruction of tumor micrometastases and circulating cancer cells.
However, as regards the mutated cfDNA in the plasma of colorectal
cancer patients, no mutated counterpart has been found in the cells of
the Ficoll layer where micrometastatic cells should be present [2]. In
addition, the fact that this layer is used as a normal control in microsat-
ellite analysis indicates the lack of cancer cells in this material. On theonkhorst).basis of this information, the hypothesis was rendered erroneous [3].
There remain three more possible sources that may account for the
occurrence of cfDNA, namely: apoptosis, necrosis, and active cellular
secretion [4].
In most cases where plasma or serum DNA is subject to electropho-
resis, a ladder pattern reminiscent to that obtained by apoptotic cells is
seen [5]. Typically, these fragment sizes relate to multiples of
nucleosomal DNA stretches, ranging from 150 to 1000 bp. Jiang et al.
have reported a distinct size of 166 bp for the cfDNA of hepatocellular
carcinoma (HCC) patients. This observation is consistent with their pre-
vious analyses on maternal blood [6], and similar results have been ob-
tained by other independent groups [7–9]. Suzuki and colleagues
characterized the cfDNA of healthy humans and demonstrated a size
distribution between 61 and 567 bp, with a prominent peak between
161 and 170 bp. Since DNA fragments derived from necrotic cells are
normally larger than 10,000 bp [10], these ﬁndings suggest an apoptotic
origin for the bulk of cfDNA in diseased as well as healthy individuals
[11–13]. In contrast, others have observed larger fragments of cfDNA
in the blood of cancer patients, which suggests an origin from necrosis
[14–18]. An argument against necrosis as the primary pathway for
cfDNA release comes from observations that cfDNA levels decrease by
approximately 90% following radiation therapy. If necrosis ensued,
one would not expect a decline but a surge in cfDNA concentration
[19,20]. However, it can also be argued that the reduction of cfDNA
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healthy cells by the radiation [18].
On the other hand, many studies indicate that a signiﬁcant fraction
of cfDNA is derived from active cellular secretions, in which newly syn-
thesized DNA in associationwith a lipid-protein complex is released in a
homeostatic manner [21–25]. In 2010, Gahan termed this protein com-
plex “the virtosome” [26]. Since then, other mobile protein complexes
such as Argonaute2 [27] and high density lipoprotein [28] have been
shown to be associated with nucleic acids and occur in the extracellular
environment. Furthermore, cells have been shown to release extracellu-
lar vesicles, such as exosomes and prostasomes, which contain highly
speciﬁc nucleic acids that often relate to the cell fromwhich it originat-
ed [29–31].
It is evident that the origin of cfDNA is still elusive. Although most
evidence suggests that the release of cfDNA is mainly a consequence
of apoptosis, it is becoming increasingly clear that cfDNA may be re-
leased bymore than onemechanism. Itmay also be of particular interest
that Jiang and co-workers have detected a small amount of mitochon-
drial DNA and not only demonstrated that the fragments are shorter
than that of nuclear DNA but also more abundant in HCC patients than
in healthy subjects [32]. Since many of the confounding factors that af-
fect the release of cfDNA in vivo are absent in cell cultures, we propose
that many of the stumbling blocks encountered in in vivo cfDNA studies
can be partially circumvented by in vitromodels. Unfortunately, in vitro
analyses of cfDNA are currently lacking. For this reason, the aim of this
work was to assess the release and composition of cfDNA from cultured
human osteosarcoma cells (143B) and to gauge its potential use for elu-
cidating the nature of cfDNA. The release pattern of cfDNA was charac-
terized over time, and the sizes of the cfDNA fragments at each of these
intervals were evaluated. Apoptosis, necrosis, and the cell cycle proﬁles
were also investigated at different time intervals using ﬂow cytometry.
2. Materials and methods
2.1. Cell culturing and growth medium processing
The human bone cancer (osteosarcoma) cell line 143B was ob-
tained from the American Type Culture Collection (ATCC® CRL-
8303™). Cells were grown in Dulbecco's modiﬁed Eagle's medium
(Hyclone DMEM/high glucose) (Thermo Scientiﬁc; #SH30243.01)
containing 4 mM L-glutamine, 4500 mg/L glucose, and sodium pyru-
vate. It was further fortiﬁed with 10% fetal bovine serum (FBS)
(Biochrom; #S0615) and 1% penicillin/streptomycin (Lonza; #DE17-
602E). Cells were incubated in humidiﬁed atmosphere containing 5%
CO2 at 37 °C. Cells were seeded and cultured in bulk in 175 cm2 cell cul-
ture ﬂasks (Corning; #431080) (36 mL growth medium) and grown to
conﬂuency. To detach the cells from theﬂask surface, theywerewashed
with phosphate-buffered saline (PBS) (Sigma; #SLBJ5110V) and then
incubated for 5–10 min at 37 °C with 0.25% trypsin (Lonza; #2
MB258). After trypsinization, the cells were redistributed equally into
twelve 75 cm2 ﬂasks, each containing 12 mL growth medium. The
cells were then grown for 12 h, after which the growth medium was
renewed. After this time, pairs of ﬂasks were incubated for 4, 8, 12, 16,
20 and 24 h, respectively. At the end of incubation, the growthmedium
was collected in 15 mL nuclease-free tubes (Ambion; #3108090) and
then centrifuged at 10,000 ×g for 10 min and transferred to fresh
15 mL tubes. The samples were then stored at−80 °C until extraction.
In concurrence with growthmedium collection, the cells were collected
by trypsinization, which was then used for extraction and determina-
tion of total cellular protein content. This experiment was then also re-
peated for 28, 32, 36 and 40 h, respectively.
2.2. Extraction and quantiﬁcation of cellular protein
Total cellular protein was liberated by sonication with the Bioruptor
UCD-200 (Diagenode). Before usage, the Bioruptor was cooled to 4 °Cusing distilled water and ice. Samples were then vortexed and loaded
into the Bioruptor wells. Sonication settings were: power, H-position
(high); sonication cycle, 30 s on/30 s off; total sonication time, 5–10 cy-
cles. Halfway through sonication, samples were removed and vortexed.
Proteins were quantiﬁed with the Qubit® 2.0 Fluorometer
(Invitrogen, Life Technologies). This method relies on the design of a
standard curve with proteins included in the Qubit® Protein Assay kit
(0, 200 and 400 ng/μL). Brieﬂy, working solution was prepared by
adding a volume of 1 μL of Qubit™ reagent to 199 μL of Qubit™ buffer.
For the standards, 10 μL was mixed with 190 μL of working solution in
0.5 mL Qubit® assay tubes. For the cellular protein samples, 2 μL was
added to 198 μL of working solution. The tubes were vortexed for 3 s
and then incubated for 15 min at room temperature. After incubation,
the tubes were inserted into the Qubit® 2.0 Fluorometer and the stock
concentration readings were noted. First, to evaluate the precision of
the Qubit® 2.0 Fluorometer a stock solution of bovine serum albumin
(BSA) (2 mg/mL) was diluted to 0.15, 0.20, 0.25, and 0.30 mg/mL and
then quantiﬁed. It was then calculated that the Qubit is 93% accurate,
which was sufﬁcient for the purposes of subsequent experiments. This
way, more tedious analyses like the BCA assay could be circumvented.
2.3. Extraction of cell-free DNA
CfDNA was extracted with the NucleoSpin Gel and PCR Clean-up kit
(Macherey-Nagel, Düren, Germany; #1502/001), according to the
manufacturer's PCR clean-up instructions. Brieﬂy, samples were re-
moved from the−80 °C freezer and thawed at 37 °C in a temperature
controlled water bath. After incubation, the samples were vortexed
and centrifuged brieﬂy. For each biological replicate, cfDNAwas extract-
ed in triplicate. For every sample, 600 μL of growth mediumwas mixed
with 1200 μL of binding buffer. Samples were then vortexed, the entire
volume of growth media was added to the spin column in small regi-
ments, and centrifuged at 11,000 ×g for 1 min at room temperature.
The columns were then washed twice, followed by the elution of
cfDNA into 20 μL of elution buffer.
2.4. Quantiﬁcation of cell-free DNA
PCR ampliﬁcation of cfDNA was measured using a real-time quanti-
tative assay for theβ-globin gene. All assayswere performed on a Rotor-
Gene Q detection system (Qiagen) using a 72 well ring-setup. The reac-
tion mixture consisted of 2 μL DNA and 23 μL master mix, which was
composed of 8.1 μL H2O, 12.5 μL TaqMan Universal MasterMix (Life
Technologies; #1502032), 0.4 μL of 10 μM dual ﬂuorescent probe 5′-
(FAM)AAG GTG AAC GTG GAT GAA GTT GGT GG(TAMRA)-3′, and 1 μL
of 10 μM forward and reverse primers, respectively. The primers used
were: F1, 5′-GTG CAC CTG ACT CCT GAG GAG A-3′, and R1, 5′-CCT TGA
TAC CAA CCT GCC CAG-3′. These probe and primers were synthesized
by Integrated DNA Technologies (IDT, Whitehead Scientiﬁc). PCR condi-
tions were set to: 95 °C for 10min, followed by 45 cycles of 15 s denatur-
ation at 95 °C, 1 min annealing at 60 °C, followed by 30 s extension at 72
°C. Sequence data of β-globin is attainable from GenBank (accession
number: U01317). The absolute concentration of the target genewas cal-
culated by using a standard curve. In this study, a standard curve was
generated using ﬁve-fold serial dilutions of genomic DNA (50,000,
5000, 500, 50 and 5 pg/μL). Each biological replicatewas quantiﬁed in du-
plicate, and triplicates of the standard curve were included in each run
(only assays with R2 values N0.99 for the standard curve were used).
2.5. Fragment size evaluation of cell-free DNA
The size of cfDNA extracted at the different time intervals were ana-
lyzed by capillary electrophoresis (CE). This was done on a microchip
using the High Sensitivity DNA kit and an Agilent 2100 Bioanalyzer
(Agilent Technologies Inc., Santa Clara, CA) equipped with Expert
2100 software. The assay was performed according to the instructions
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analogously to CE, they are normalized to a ladder and two DNA
markers, and are represented as a virtual band. The software then auto-
matically calculates the size of each band, and is represented as an
electropherogram.
2.6. Flow cytometric detection of apoptosis and necrosis using the FITC
annexin V assay
The BD Annexin V FITC assay (BD Biosciences) was utilized to deter-
minewhether the apoptotic proﬁle of 143B cells differ at speciﬁc time in-
tervals. 143B cells were washed twice with PBS and resuspended in 1×
binding buffer at a concentration of 1 × 106 cells/mL at different time in-
tervals (4, 12, 24 and 40 h). 100 μL of this solutionwas then transferred to
12 × 75 mm round bottom (conical) tubes (BD Biosciences) and mixed
with 5 μL of FITC Annexin V and 5 μL of propidium iodide (PI). Samples
were then vortexed and incubated in the dark at room temperature for
20 min. After incubation, 100 μL of 1X binding buffer was added to each
tube and then analyzed using the BD FACSVerse System and BD FACSuite
Software. For a positive apoptosis control, 143B cells were treated with
650 μMhydrogen peroxide for 4 h. Unstained cells were included for set-
tings optimisation of the ﬂow cytometer.
2.7. Flow cytometric detection of apoptosis with the TUNEL assay
An APO-BrdU™ TUNEL assay kit (Molecular Probes, Invitrogen) was
used for the detection of DNA fragments as recommended by the man-
ufacturer, with slight modiﬁcations. Brieﬂy, an amount of 2 × 106 cells
were suspended in 0.5 mL PBS. Cells were counted using the scepter
(Merck, Millipore) and ﬁxed by adding the cell suspension to 5 mL of
1% (w/v) paraformaldehyde (Fluka) on ice for 15 min. After ﬁxation,
the cells were centrifuged for 5 min at 300 ×g, and the supernatantFig. 1. Time-course characteristics of cfDNA released from 143 B cells. A. Bar graph showing th
renewal. B. Bar graph showing the amount of cfDNA released by 143B cells after 28–40 h of
cfDNA in 1 μL of a total of 20 μL of elution buffer obtained from 600 μL of growth medium. C
total cellular protein.was discarded. The cells were washed twice with 5 mL of PBS, and the
pellet was resuspended in 0.5 mL of PBS followed by 5 mL of ice-cold
70% (v/v) ethanol. The cell suspensions were stored in a−20 °C freezer
until analyzed for fragmented DNA. On the day of analysis, the samples
were resuspended in PBS and 1 mL aliquots (approximately 1 × 106
cells) were removed and placed in 12 × 75 mm ﬂow cytometry tubes
(BD Biosciences). The cell suspensions were then centrifuged for
5 min followed by the removal of the remaining ethanol by aspiration.
The cell suspensions were washed twice with 1 mL of wash buffer
(Apo- BrdU™ TUNEL assay kit), and the supernatants were removed
by aspiration. Then, the pellet was resuspended in 50 μL of freshly pre-
pared DNA-labeling solution (Apo-BrdU kit) containing 10 μL reaction
buffer, 0.75 μL of TdT enzyme, 8.0 μL of BrdUTP and 31.25 μL dH2O.
The cells were incubated in the DNA-labeling solution for 60 min at 37
°C. The cells were gently shaken every 15 min to keep it in suspension.
At the end of the incubation time, the cells were washed twice in
1 mL of rinse buffer (Apo-BrdU kit) by centrifugation at 300 ×g for
5 min at room temperature.
The supernatantswere removed by aspiration, and the pelletwas re-
suspended in 100 μL of freshly prepared antibody staining solution con-
taining 5 μL Alexa Fluor® 488 dye-labeled anti-BrdU antibody and 95 μL
rinse buffer. Cells were incubated in this solution for 30 min at room
temperature in a darkened room. After incubation, 0.5 mL of propidium
iodide/RNase A staining buffer (Apo- BrdU™ TUNEL assay kit) was
added. Cells were analyzed for DNA fragmentation using the BD
FACSVerse System and BD FACSuite Software.
2.8. Flow cytometric cell cycle analysis
Cells were cultured as described in section 2.1. After 12 h of incuba-
tion, the pointwheremediumwas renewed, 5-ethynyl-2′-deoxyuridine
(EdU) was added to a ﬁnal concentration of 10 μM to each ﬂask ande amount of cfDNA released by 143 B cells after 4–24 h of incubation following medium
incubation following medium renewal. The value of each bar represents the amount of
& D Represents the amount of cfDNA released at each time-point normalized in terms of
Fig. 3. Bar graph showing the amount of cfDNA released by 143B cells after 4–40 h of in-
cubation following medium renewal. CfDNA was quantiﬁed by capillary electrophoresis
using an Agilent 2100 Bioanalyzer.
Fig. 2.Capillary electropherograms showing the size of cfDNA isolated after incubation at various times followingmedium renewal. In each electropherogram twomajor peaks can be seen,
one at 35 bp and one at approximately 10,000 bp. These peaks correspond to the two size markers. The relative ﬂuorescence of these markers is then used to calculate the size of the un-
known samples. Thus, any deviation from the baseline, excluding the markers, indicates the size of cfDNA.
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with the Click-iT® Edu Alexa Fluor® 488 Cell Proliferation Kit (Molecular
Probes, Invitrogen) according to the instructions of the manufacturer.
Brieﬂy, harvested cells were washed once with 1% BSA in PBS and
pelleted by centrifugation at 500 ×g for 5 min at room temperature.
The supernatant was removed and the pellet resuspended at a density
of 1 × 107 cells/mL in PBS. To ﬁxate cells, 100 μL of the cell suspension
was mixed with 100 μL of Click-iT® ﬁxative agent in a 12 × 75 mm
ﬂow tube and incubated in a dark room for 15 min. After incubation,
cells werewashedwith 3mL of 1% BSA in PBS, pelleted, and the superna-
tantwas discarded. The pelletwas then dislodged, resuspended rigorous-
ly, andmixedwith 100 μL Triton®X-100-based permeabilization reagent
and then incubated for 30min at room temperature in a dark room. After
incubation, cells were washed with 3 mL of 1% BSA in PBS, pelleted, and
the supernatant was discarded. The Click-iT® EdU reaction cocktail was
prepared as recommended by the manufacturer and 5 mL was added to
each cell pellet. Samples were incubated for 30min at room temperature
in a dark room and thenwashedwith 3mL of 1% BSA in PBS and pelleted.
After the supernatant was discarded 0.5 mL of 1% BSA in PBS was added
to the pellet. For staining of cellular DNA, 5 μL of Ribonuclease (RNAse
A) was ﬁrst added to each sample and mixed, after which 2 μL of the
Click-iT® EdU CellCycle 488-red (7-AAD) and 2 μL of Propidium iodide
was added to each sample and mixed again and then incubated at
room temperature for 30 min. After incubation, cells were transferred
to ice until analysis with a BD FACSVerse System and BD FACSuite
Software.
2.9. Flow cytometry instrumentation and data analysis
Fluorescence of single cells was measured by a FACSVerse™ bench
top ﬂow cytometer equipped with blue (488 nm) and red (640 nm) la-
sers. Events were acquired on BD FACSuiteTM software, version 1
(Becton & Dickson, Mountain View, CA, USA). Ampliﬁcation of signals
were carried out at logarithmic scale and measurement of events plot-
ted on forward light scatter (FSC), side light scatter (SSC), green ﬂuores-
cent (FL1) and red ﬂuorescent (FL2). A gating strategy was used to
distinguish the ﬂuorescently labeled cell population from unstained
populations. A total of 10 000 events as deﬁned by gates, were counted.
Positive as well as stained and unstained negative controls were includ-
ed in each analysis. The FACSVerse were calibrated using FACSuite™
CS&T research beads. Data was processed with FCS Express V4 software
(DeNovo Software, CA, USA). Gateswere set on the dot plot FSC and SSC
during analysis. The geometric means of ﬂuorescence for all theparameters were calculated from the respective histograms or two pa-
rameter ﬂuorescence dotplots.
Fluorescence results were expressed in arbitrary units as mean ﬂuo-
rescence intensity (MFI) and cell counts were expressed as percentage.
Flow cytometry samples were analyzed blind, and the researcher re-
sponsible for analyzing ﬂow cytometry data was blinded to the objec-
tives and outcome of the experiments.
2.10. Treating growth medium with denaturing agents
cfDNAwas isolated as described in section 2.3, except prior to extrac-
tion the growth medium was incubated with SDS (0.05%), proteinase K
(1.5 mg/mL), and a combination of the two for 30 min, respectively. In
the cases where SDS was used, buffer NTB was used instead of buffer
NTI. As the kit makes no suggestions regarding the use of proteinase K,
buffer NTI was used in this case. Since the medium of all the samples in
the previous experiment was snap-frozen, an experiment was done to
determine whether the high yields of cfDNA are wholly or only partly
due to the addition of proteinase K, and not partly due to snap-freezing.
To do this, four different scenarios were compared: (1) cfDNA was ex-
tracted from growth medium directly after collection, (2) growth medi-
um was treated with proteinase K immediately after collection,
followed by cfDNA extraction, (3) growth medium was snap frozen
Fig. 4. Dot plots illustrating the amount of apoptotic and necrotic 143 B cells after different times of incubation. Flow cytometric analysis was performed on 143 B cells staining simulta-
neously with annexin-V-FITC and propidium iodide (PI). For each graph, the lower left quadrant represents viable cells, the upper left quadrant represents apoptotic cells, the upper right
quadrant represents cells in late stage apoptosis, and the lower right quadrant represents necrotic cells. Every dot corresponds to a single cell. Replicates 1, 2 and 3 of the control column
represent 143 B cells treated with 150, 300 and 600 mM of hydrogen peroxide, respectively.
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then thawed and treated with proteinase K prior to extraction.
3. Results and discussion
The origin of cfDNA is still elusive. There are several possible sources
that may account for the occurrence of cfDNA, including apoptosis, ne-
crosis, and active cellular release. In this study, the release of cfDNA
from cultured cells was evaluated in order to gauge its potential use
for elucidating the nature of cfDNA.
3.1. Kinetics of cfDNA release
Release of cfDNA was characterized over time (Fig. 1 A & B). After
growthmedium renewal, the amount of cfDNA increased incrementally,Fig. 5. Summaryof theprocesseddata obtainedby the FITCAnnexinVﬂowcytometric assay. A illus
time-points. B illustrates the percentage of viable 143 B cells at each time-point. These values reprnotably peaked after 24 h, and plateaued at a much lower level thereaf-
ter. Since the amount of cells increase over time, this is not surprising.
However, when the values were normalized in terms of total cellular
protein the tendency did not change, suggesting that more cfDNA is re-
leased per cell (Fig. 1 D & C). In the case where capillary electrophoresis
was used to quantify cfDNA, the same pattern was obtained (Fig. 3). This
phenomenon can be seen in at least three other reports in the literature
[33–35]. Morozkin et al. assessed the kinetics and composition of cfDNA
released by A431 (epidermoid carcinoma) and HeLa (cervical cancer)
cells over 48 h. It was demonstrated that cfDNA concentration increases
over time, and electrophoretic analysis indicated amolecular weight be-
tween 0.4 and 10 kilobase pairs. This suggested that the cfDNA is neither
from apoptotic nor necrotic origin [34]. A few years later, they repeated
the experiment but also assessed the DNA released by primary HUVEC
(human umbilical vein endothelial) cells and mycoplasma infectedtrates thepercentage of apoptotic, necrotic, and late-stage apoptotic 143B cells at thedifferent
esent the averages of the replicates showed in Fig. 3. Error bars indicate standard deviation.
Fig. 6. Dot plots illustrating the detection of DNA fragmentation in 143B cells at different times as analyzed with the TUNEL assay by ﬂow cytometry. The ﬂuorescence of DNA content is
plotted against Anti-BrdU alexa ﬂuor 488 incorporation. Replicate 1 shows the positive control and replicate 2 shows the negative control. For each graph, the lower left quadrant repre-
sents viable cells, while the upper left quadrant represents apoptotic cells.
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and beginning of the exponential growth phase. They considered this
to be evidence for the active release of cfDNA [33]. Choi and co-
workers designed a similar experiment for Jurkat (human T lymphocyte)
and U937 (pleural effusion) cells. However, in addition to normal condi-
tions, apoptosis and necrosis were induced in both cell lines. In the case
of apoptosis, cfDNA concentration increased over time and also peaked
rather dramatically after 24 to 48 h. CfDNA from untreated cells in-
creased only slightly at these times. On the other hand, necrotic cells
showed a decline of cfDNA over time. These results suggest that the re-
lease of cfDNA is mainly a consequence of apoptosis, but also suggests
that cfDNA may be released by more than one mechanism [35].
3.2. Size of cfDNA
To examine the size of cfDNA isolated at the different time points,
sampleswere subject to capillary electrophoresis (Fig. 2). After 4 h of in-
cubation a prominent peak at 166 bpwas observed, which is consistentFig. 7.Dot plots illustrating the proliferation of 143B cells at different times as analyzed with th
against Edu alexa ﬂuor 488 staining.with the literature and indicates an origin from apoptosis [32]. Howev-
er, this peak diminished incrementally and disappeared after 24 hwhen
a newpeak of approximately 2000bpdominated the scene. After 40h of
incubation, the cfDNA resemblesmultiples of nucleosomal repeats, with
peaks forming at approximately 160, 340 and 540 bp, also suggesting an
origin from apoptosis. These observations demonstrate a clear correla-
tion between an increase in the release of cfDNA and the occurrence
of higher molecular weight DNA. As far as we know, this distinct size
of ~2000 bp has not yet been reported. This is peculiar, because its
size suggests that it is neither from apoptotic nor necrotic origin.
3.3. Measurement of apoptosis and necrosis
To corroborate the observations made by electrophoretic analysis,
and to help elucidate the origin of the cfDNA occurring at the different
time points, the cells at each of the times correlating with the time-
course study was analyzed for apoptosis, necrosis and cell cycle phase
using three different ﬂow cytometric assays. The FITC Annexin V assaye Click-it EdU kit by ﬂow cytometry. The DNA content (position in the cell cycle) is plotted
Fig. 8.Histogram and bar graphs showing the cell cycle distribution of 143 B cells at different points in time. In A, 4, 12, 24 and 40 h are represented by black, red, blue and purple, respec-
tively. B shows the percentage cells in each phase as analyzed by FCS Express Multicycle. The high percentages of cells in the G0/G1 and S-phases are indicative of a fast growing cell
population.
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showed almost no apoptosis or necrosis (Figs. 4 & 5). Barring the time
point of 4 h, these resultswere corroborated by the TUNEL assay (Fig. 6).
3.4. Cell cycle assessment
The assay used tomeasure cell proliferation reveals that, after 24 h of
growth following medium renewal, there is a decline of cells in the S
phase and signiﬁcant increase of cells in the sub G0/G1 phase (Figs. 7
& 8). This suggests that the increase of cfDNA after 24 h of incubation
is not associatedwith the process of DNA replication. The possible origin
of cfDNA, in association with lipid-protein complexes (virtosomes), has
been reviewed by Gahan where he reported literature showing that
cfDNA in this form is released from both dividing and differentiated
cells [26]. Since differentiated cells tend to be held in either the G0 or
G1 phases of the cell cycle, Gahan suggested that this could be the
realm in which cfDNA is synthesized, and that it is not likely related to
mitotic DNA synthesis [26]. Our results support this notion.
3.5. Further characterization of cfDNA
To determinewhether the cfDNA released from143 B cells after 24 h
of incubation could be similar to the virtosomes described by Gahan,
growthmediumwas treated with denaturing agents prior to cfDNA ex-
traction, and were compared to untreated samples (Fig. 9). In all cases,
the yield of cfDNA was increased considerably by the addition of dena-
turing agents. Since it has been previously described that cfDNA is disso-
ciated from the lipid-protein complex by freezing and thawing or by
treatment with deoxycholate [36], the results of this experimentFig. 9. The effect of treating growth medium with denaturing agents prior to extraction of cfDN
(1.5 mg/mL), and a combination of the two were evaluated. In the cases where SDS was used,
extraction and snap-freezing, with and without the use of proteinase K. It is clear that, when th
and that the high yields can be ascribed solely to the addition of proteinase K.suggest that cfDNA is associated with proteins. Whether these proteins
are simply nucleosomes, virtosomes, or extracellular vesicles remains
unclear, and requires further experimentation.
4. Conclusion
Most in vivo studies report that the occurrence of cfDNA is associated
with apoptosis or necrosis. However, the results obtained by this study
suggest that the release of cfDNA from cultured 143 B cells after 24 h of
incubation is not a consequence of apoptosis, necrosis, or a product of
DNA replication, but primarily a result of actively released DNA, perhaps
in association with a protein complex. Although other research groups
have arrived at the same conclusion, very little attention has been
drawn to this discovery.
The literature suggests that the purpose of actively released DNA is
for the DNA to act as an intercellular messenger of sorts [37,38]. This
is achieved by entering target cells and either integrating into the host
genome, or to transiently elicit a biological effect [26]. Thus far, to men-
tion the most prominent, the transfer of cfDNA between different cells
has been implicated in the induction of tolerance against detrimental
substances [40], immunomodulation [41], and the development of me-
tastasis [42,43]. The latter has been demonstrated to occur in vitro [44]
and in vivo [43]. In addition, results by Bergsmedh et al. suggest that
the lateral transfer of cfDNA can not only mediate metastasis, but also
generate the genetic instability necessary for malignancy [45]. On the
other hand, Garcia-olmo and colleagues have recently shown that
cfDNA derived from non-dividing healthy cells can halt tumor growth
[46]. A recent review lends support to these ﬁndings and further illus-
trates the functional diversity of cfDNA [47]. It was found that apoptoticA. A. The effect of the addition of denaturing agents. The use of SDS (0.05%), proteinase K
buffer NTB was used instead of buffer NTI. B. A comparison of cfDNA yield between direct
e averages are calculated, snap-freezing does not increase the amount of cfDNA extracted
164 A.J. Bronkhorst et al. / Biochimica et Biophysica Acta 1863 (2016) 157–165death of stressed (irradiated) cells result in the release of oxidized
cfDNA into circulation. This may serve as a biomarker of stress. In ad-
dition, it was demonstrated that these oxidized cfDNA molecules
may confer survivability to other malignant cells by augmenting
their resistance to radiation therapy. This is known as the bystander
effect [39].
We further suggest, keeping in mind that cfDNA is readily trans-
ferred between cells, the possibility that cfDNA may play a role in the
regulated generation of somatic genome variation. In addition, DNA
has been detected in extracellular vesicles released by prostate cells
that have been shown to interact with sperm cells [48,49]. This suggests
that cfDNA may also be a potential bridge for information transfer be-
tween the soma and the germ line, which is still considered to be an un-
bridgeable chasm.
Although many aspects of the phenomenon of cfDNA messaging re-
main obscure, it is clear that the possibilities are intriguing. The observed
messaging functions of cfDNA defy our traditional views of intercellular
communication, especially relating to pathology. Furthermore, if cfDNA
plays a role in somatic genome variation and transgenerational inheri-
tance, it would strongly challenge the neo-Darwinian synthesis of evolu-
tion. Since cells in culture are isolated from the confusing variables
encountered in vivo, in vitro characterization of themechanisms thatme-
diate the reactions of cfDNA should provide useful insight into its origin.
This information is crucial for expediting the translation of in vivo cfDNA
analyses to clinical practice, since it will provide novelmarkers for the di-
agnosis and therapy monitoring of several diseases, while ultimately
leading to the treatment of certain diseases.
There are many ways in which cfDNA can be further characterized
in vitro. For instance, the effect of cfDNA transfection on recipient cells
can be evaluated by measuring cell viability, followed by metabolic
and gene expression proﬁling. In addition, intracellular trafﬁcking of
these molecules can be traced by radioactive labeling, or alternatively
by non-radioactive methods as described by Mansﬁeld et al. [50].
Since cfDNA is often associated with extracellular vesicles such as
exosomes, its cellular release and uptake could be visualized by live-
cell microscopy using lipophilic dye and amino-reactive ﬂuorophore la-
beling. This technique has been described by Tian et al. [51]. Arguably
the best way to understand themolecular production of cfDNA is to ex-
amine its composition, in other words its sequence information. In the
last couple of years, only a small number of papers have been published
on the large scale sequencing of cfDNA. However, the objective of these
studieswas not to fully characterize cfDNA, but rather the sequence am-
pliﬁcation of products to identify a small number of genes, while others
have focused on methylation speciﬁc sequencing, or on the determina-
tion of molecular size [32,52–54]. Moreover, these studies were based
on blood samples. The results of this study suggest that sequencing of
cfDNA released by cultured cells may prove to be a useful way to cir-
cumvent the variables encountered in in vivo studies that may produce
confusing sequencing results. In conclusion, the results of the current
study demonstrate the potential of in vitro cfDNA analysis to aid in the
elucidation of the nature of cfDNA.Transparency Document
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